Cecilia Acuti Martellucci, Angelo Capodici, Graziella Soldato, Matteo Fiore, Enrico Zauli, Roberto Carota, Marco De Benedictis, Graziano Di Marco, Rossano Di Luzio, Maria Elena Flacco, Lamberto Manzoli
{"title":"COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province.","authors":"Cecilia Acuti Martellucci, Angelo Capodici, Graziella Soldato, Matteo Fiore, Enrico Zauli, Roberto Carota, Marco De Benedictis, Graziano Di Marco, Rossano Di Luzio, Maria Elena Flacco, Lamberto Manzoli","doi":"10.17179/excli2025-8400","DOIUrl":null,"url":null,"abstract":"<p><p>Anecdotal reports suggested an association between SARS-CoV-2 vaccination and some cancers, but no formal assessment has been published. This population-wide cohort analysis was aimed at evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. Using National Health System official data, the entire population of the Pescara province, Italy was followed from June 2021 (six months after the first vaccination) to December 2023. Cox models were adjusted for age, gender, previous SARS-CoV-2 infection, and selected comorbidities. Of the 296,015 residents aged ≥11 years, 16.6% were unvaccinated, 83.3% received ≥1 dose, and 62.2% ≥3 doses. Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death, and a slightly higher likelihood of hospitalization for cancer (HR: 1.23; 95% CI: 1.11-1.37). The latter association was significant only among the subjects with no previous SARS-CoV-2 infection, and was reversed when the minimum time between vaccination and cancer hospitalization was set to 12 months. The subjects who received SARS-CoV-2 vaccination showed a substantial reduction in all-cause mortality, and a risk of cancer hospitalization that varied by infection status, cancer site, and the minimum lag-time after vaccination. Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary. See also the graphical abstract(Fig. 1).</p>","PeriodicalId":12247,"journal":{"name":"EXCLI Journal","volume":"24 ","pages":"690-707"},"PeriodicalIF":4.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381369/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EXCLI Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.17179/excli2025-8400","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Anecdotal reports suggested an association between SARS-CoV-2 vaccination and some cancers, but no formal assessment has been published. This population-wide cohort analysis was aimed at evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. Using National Health System official data, the entire population of the Pescara province, Italy was followed from June 2021 (six months after the first vaccination) to December 2023. Cox models were adjusted for age, gender, previous SARS-CoV-2 infection, and selected comorbidities. Of the 296,015 residents aged ≥11 years, 16.6% were unvaccinated, 83.3% received ≥1 dose, and 62.2% ≥3 doses. Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death, and a slightly higher likelihood of hospitalization for cancer (HR: 1.23; 95% CI: 1.11-1.37). The latter association was significant only among the subjects with no previous SARS-CoV-2 infection, and was reversed when the minimum time between vaccination and cancer hospitalization was set to 12 months. The subjects who received SARS-CoV-2 vaccination showed a substantial reduction in all-cause mortality, and a risk of cancer hospitalization that varied by infection status, cancer site, and the minimum lag-time after vaccination. Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary. See also the graphical abstract(Fig. 1).
期刊介绍:
EXCLI Journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.
The journal is particularly keen to keep a broad view of science and technology, and therefore welcomes papers which bridge disciplines and may not suit the narrow specialism of other journals. Although the general emphasis is on biological sciences, studies from the following fields are explicitly encouraged (alphabetical order):
aging research, behavioral sciences, biochemistry, cell biology, chemistry including analytical chemistry, clinical and preclinical studies, drug development, environmental health, ergonomics, forensic medicine, genetics, hepatology and gastroenterology, immunology, neurosciences, occupational medicine, oncology and cancer research, pharmacology, proteomics, psychiatric research, psychology, systems biology, toxicology